Mastocytosis, Systemic
A group of disorders caused by the abnormal proliferation of MAST CELLS in a variety of extracutaneous tissues including bone marrow, liver, spleen, lymph nodes, and gastrointestinal tract. Systemic mastocytosis is commonly seen in adults. These diseases are categorized on the basis of clinical features, pathologic findings, and prognosis.
Subtype terms (1)
More specific conditions that are subtypes of Mastocytosis, Systemic in the MeSH hierarchy.
- Leukemia, Mast-Cell
27 drugs (20 approved, 7 experimental)
Drugs by status
Approved for this indication (2)
Phase 3 trials (5)
Phase 2 trials (12)
Phase 1 trials (8)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (15)
- Blueprint Medicines Corporation
- Patara Pharma
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Stanford University
- University of Groningen
- University of Bologna
- University of Naples Frederico II
- University of Minnesota
- City of Hope National Medical Center
- University of Texas at Houston
- Humboldt University
- Gemin X
- University of Picardie Jules Verne
Organization Involved with Phase 1 Indications (2)